PPARG and colitis: The loss of PPARγ in immune cells impaired the ability of PUA to ameliorate experimental colitis, strongly suggesting that PUA could modulate mucosal immune responses and therefore ameliorate gut inflammation through a PPARγ-dependent mechanism, which antagonizes NF-κB, STAT and AP-1 [66].